Opinion|Videos|May 10, 2024
The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
